
Neuroscience Antibodies and Assays
Description
Global Neuroscience Antibodies and Assays Market to Reach US$9.8 Billion by 2030
The global market for Neuroscience Antibodies and Assays estimated at US$5.9 Billion in the year 2024, is expected to reach US$9.8 Billion by 2030, growing at a CAGR of 8.9% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 8.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 8.3% CAGR
The Neuroscience Antibodies and Assays market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.2% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.
Global Neuroscience Antibodies and Assays Market - Key Trends & Drivers Summarized
What Are Neuroscience Antibodies and Assays and Why Are They Crucial?
Neuroscience antibodies and assays are essential tools used in neuroscience research to study proteins, receptors, enzymes, and other molecules involved in the functioning of the nervous system. Antibodies are used to detect and bind to specific proteins or biomarkers related to neurological diseases, while assays help measure these biomarkers and study their effects on brain function. These tools are critical for understanding the molecular mechanisms underlying neurodegenerative diseases, brain injuries, psychiatric disorders, and developmental conditions such as autism.
The use of antibodies and assays in neuroscience is indispensable for identifying disease markers, enabling early diagnosis, and developing therapeutic interventions. For example, antibodies against amyloid-beta and tau proteins are widely used in Alzheimer’s research to study the buildup of these proteins in the brain. Similarly, assays are employed to measure the activity of neurotransmitters and other signaling molecules involved in brain function. By providing precise, reproducible data, neuroscience antibodies and assays are pivotal in advancing the understanding of complex brain diseases and developing targeted treatments.
How Is the Neuroscience Antibodies and Assays Market Evolving?
The neuroscience antibodies and assays market is evolving alongside advancements in molecular biology and diagnostic technologies. One of the major trends in this market is the increasing demand for high-quality, specific antibodies that can target complex proteins involved in neurological disorders. As neuroscience research delves deeper into neurodegenerative diseases, there is a growing need for highly specific antibodies that can differentiate between healthy and diseased tissues. Companies are developing more sophisticated antibodies that target post-translational modifications, protein isoforms, and disease-specific conformations, enhancing the precision of neuroscience research.
Additionally, the rise of multiplex assays, which allow for the simultaneous detection of multiple biomarkers in a single sample, is revolutionizing neuroscience research. These assays are particularly valuable in studying complex neurological conditions, where multiple signaling pathways and proteins are involved. Advances in assay technologies, such as next-generation sequencing (NGS) and mass spectrometry-based assays, are further driving growth in the market by enabling more comprehensive analysis of brain tissue, fluids, and cells. Automation and miniaturization of assays are also becoming more prevalent, improving throughput and reducing costs for researchers.
Which Research Areas Are Leading the Adoption of Neuroscience Antibodies and Assays?
Neuroscience antibodies and assays are being widely adopted in research focused on neurodegenerative diseases, neuroinflammation, and psychiatric disorders. Alzheimer’s disease research is one of the largest users of these tools, with antibodies targeting amyloid-beta plaques and tau tangles being essential for studying disease mechanisms and potential treatments. Parkinson’s disease research also relies heavily on antibodies and assays to study the accumulation of alpha-synuclein and other proteins implicated in the disease`s progression.
Neuroinflammation, a key factor in many neurological disorders, is another area driving the use of neuroscience antibodies and assays. Researchers are using these tools to measure inflammatory markers in the brain and spinal cord, providing insights into conditions such as multiple sclerosis, traumatic brain injury, and autoimmune diseases. Psychiatric disorders, such as schizophrenia and depression, are also major areas where antibodies and assays are being used to study neurotransmitter pathways and neural circuits, with the goal of developing more targeted and effective treatments.
What Are the Key Growth Drivers in the Neuroscience Antibodies and Assays Market?
The growth in the neuroscience antibodies and assays market is driven by several factors. One of the primary drivers is the increasing prevalence of neurodegenerative diseases, particularly in aging populations. As diseases like Alzheimer’s and Parkinson’s become more common, there is a growing need for biomarkers and diagnostic tools that can aid in early detection and treatment. Another key driver is the advancement of personalized medicine, which is creating demand for more specific and sensitive antibodies and assays tailored to individual patients` needs.
Technological advancements in assay platforms, such as multiplex assays and high-throughput screening, are also accelerating the growth of this market by enabling researchers to conduct more comprehensive studies. Additionally, the increasing investment in neuroscience research, coupled with government initiatives focused on mental health and neurological diseases, is fueling the expansion of this market. The rise of biopharmaceuticals and the development of targeted therapies for neurological conditions are further driving demand for neuroscience antibodies and assays in drug discovery and development.
SCOPE OF STUDY:The report analyzes the Neuroscience Antibodies and Assays market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Offering (Consumables, Instruments); Technology (Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry, Other Technologies); End-Use (Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 11 Featured) -
- Abcam PLC
- BioLegend, Inc.
- Bio-Rad Laboratories, Inc.
- Cell Signaling Technology, Inc.
- F. Hoffmann-La Roche AG
- GenScript Biotech Corporation
- Merck KgaA
- Rockland Immunochemicals, Inc.
- Santa Cruz Biotechnology, Inc.
- Siemens Healthineers
- Tecan Group Ltd.
- Thermo Fisher Scientific, Inc.
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Global Economic Update
- Neuroscience Antibodies and Assays – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Prevalence of Neurological Diseases Drives Demand for Neuroscience Antibodies and Assays in Research and Diagnostics
- Advancements in Monoclonal and Polyclonal Antibodies Propel Growth in Neuroscience Research Applications
- Growing Focus on Biomarker Discovery for Alzheimer s and Parkinson s Diseases Expands Use of Neuroscience Antibodies in Diagnostics
- Increasing Demand for High-Specificity Antibodies Accelerates Growth in Precision Medicine for Neurological Disorders
- Advancements in Immunohistochemistry Techniques Strengthen the Business Case for Neuroscience Antibodies in Tissue Analysis
- Rising Adoption of Neuroscience Antibodies for Neuroinflammation Research Expands Market in Neurodegenerative Disease Treatment
- Growing Interest in Synaptic and Axonal Biology Propels Demand for Neuroscience Antibodies Targeting Neurotransmitter Systems
- Emerging Focus on Autoimmune Neurological Conditions Drives Growth in Antibody-Based Assays for Disease Diagnosis and Monitoring
- Increasing Use of Neuroscience Antibodies in Brain Mapping and Connectomics Expands Market for Neurobiological Research
- Advancements in CRISPR and Gene Editing Technologies Drive Demand for Neuroscience Antibodies in Genetic Research
- Growing Adoption of Neuroscience Assays in High-Throughput Screening Expands Opportunities in Drug Discovery and Development
- Rising Use of Antibody Arrays in Neuroscience Research Strengthens Growth in Multiplex Assay Technologies
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Immunochemistry / Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 2: World Historic Review for Immunochemistry / Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 3: World 15-Year Perspective for Immunochemistry / Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 5: World Historic Review for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 6: World 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Clinical Chemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 8: World Historic Review for Clinical Chemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 9: World 15-Year Perspective for Clinical Chemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 11: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 12: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 13: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 14: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 15: World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 16: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 17: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 18: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 19: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 20: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 21: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 22: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 23: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 24: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 25: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 26: World Historic Review for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 27: World 15-Year Perspective for Hospitals & Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 28: World Neuroscience Antibodies and Assays Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 29: World Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 30: World Historic Review for Neuroscience Antibodies and Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: World 15-Year Perspective for Neuroscience Antibodies and Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Neuroscience Antibodies and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 32: USA Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: USA Historic Review for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: USA 15-Year Perspective for Neuroscience Antibodies and Assays by Technology - Percentage Breakdown of Value Sales for Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 35: USA Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: USA Historic Review for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: USA 15-Year Perspective for Neuroscience Antibodies and Assays by Offering - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
- TABLE 38: USA Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: USA Historic Review for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: USA 15-Year Perspective for Neuroscience Antibodies and Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers for the Years 2015, 2025 & 2030
- CANADA
- TABLE 41: Canada Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Canada Historic Review for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: Canada 15-Year Perspective for Neuroscience Antibodies and Assays by Technology - Percentage Breakdown of Value Sales for Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 44: Canada Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Canada Historic Review for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: Canada 15-Year Perspective for Neuroscience Antibodies and Assays by Offering - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
- TABLE 47: Canada Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Canada Historic Review for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: Canada 15-Year Perspective for Neuroscience Antibodies and Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers for the Years 2015, 2025 & 2030
- JAPAN
- Neuroscience Antibodies and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 50: Japan Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Japan Historic Review for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Japan 15-Year Perspective for Neuroscience Antibodies and Assays by Technology - Percentage Breakdown of Value Sales for Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 53: Japan Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Japan Historic Review for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Japan 15-Year Perspective for Neuroscience Antibodies and Assays by Offering - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
- TABLE 56: Japan Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Japan Historic Review for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Japan 15-Year Perspective for Neuroscience Antibodies and Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers for the Years 2015, 2025 & 2030
- CHINA
- Neuroscience Antibodies and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 59: China Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: China Historic Review for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: China 15-Year Perspective for Neuroscience Antibodies and Assays by Technology - Percentage Breakdown of Value Sales for Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 62: China Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: China Historic Review for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: China 15-Year Perspective for Neuroscience Antibodies and Assays by Offering - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
- TABLE 65: China Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: China Historic Review for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: China 15-Year Perspective for Neuroscience Antibodies and Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers for the Years 2015, 2025 & 2030
- EUROPE
- Neuroscience Antibodies and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 68: Europe Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Europe Historic Review for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: Europe 15-Year Perspective for Neuroscience Antibodies and Assays by Technology - Percentage Breakdown of Value Sales for Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 71: Europe Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Europe Historic Review for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: Europe 15-Year Perspective for Neuroscience Antibodies and Assays by Offering - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
- TABLE 74: Europe Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Europe Historic Review for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: Europe 15-Year Perspective for Neuroscience Antibodies and Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers for the Years 2015, 2025 & 2030
- TABLE 77: Europe Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 78: Europe Historic Review for Neuroscience Antibodies and Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Europe 15-Year Perspective for Neuroscience Antibodies and Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
- FRANCE
- Neuroscience Antibodies and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 80: France Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: France Historic Review for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: France 15-Year Perspective for Neuroscience Antibodies and Assays by Technology - Percentage Breakdown of Value Sales for Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 83: France Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: France Historic Review for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: France 15-Year Perspective for Neuroscience Antibodies and Assays by Offering - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
- TABLE 86: France Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: France Historic Review for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: France 15-Year Perspective for Neuroscience Antibodies and Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers for the Years 2015, 2025 & 2030
- GERMANY
- Neuroscience Antibodies and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 89: Germany Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Germany Historic Review for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Germany 15-Year Perspective for Neuroscience Antibodies and Assays by Technology - Percentage Breakdown of Value Sales for Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 92: Germany Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Germany Historic Review for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Germany 15-Year Perspective for Neuroscience Antibodies and Assays by Offering - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
- TABLE 95: Germany Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Germany Historic Review for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Germany 15-Year Perspective for Neuroscience Antibodies and Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers for the Years 2015, 2025 & 2030
- ITALY
- TABLE 98: Italy Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Italy Historic Review for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Italy 15-Year Perspective for Neuroscience Antibodies and Assays by Technology - Percentage Breakdown of Value Sales for Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 101: Italy Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Italy Historic Review for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Italy 15-Year Perspective for Neuroscience Antibodies and Assays by Offering - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
- TABLE 104: Italy Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Italy Historic Review for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Italy 15-Year Perspective for Neuroscience Antibodies and Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Neuroscience Antibodies and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 107: UK Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: UK Historic Review for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: UK 15-Year Perspective for Neuroscience Antibodies and Assays by Technology - Percentage Breakdown of Value Sales for Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 110: UK Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: UK Historic Review for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: UK 15-Year Perspective for Neuroscience Antibodies and Assays by Offering - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
- TABLE 113: UK Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: UK Historic Review for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: UK 15-Year Perspective for Neuroscience Antibodies and Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: Rest of Europe Historic Review for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: Rest of Europe 15-Year Perspective for Neuroscience Antibodies and Assays by Technology - Percentage Breakdown of Value Sales for Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: Rest of Europe Historic Review for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 121: Rest of Europe 15-Year Perspective for Neuroscience Antibodies and Assays by Offering - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
- TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: Rest of Europe Historic Review for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 124: Rest of Europe 15-Year Perspective for Neuroscience Antibodies and Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Neuroscience Antibodies and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: Asia-Pacific Historic Review for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 127: Asia-Pacific 15-Year Perspective for Neuroscience Antibodies and Assays by Technology - Percentage Breakdown of Value Sales for Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 129: Asia-Pacific Historic Review for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 130: Asia-Pacific 15-Year Perspective for Neuroscience Antibodies and Assays by Offering - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
- TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Asia-Pacific Historic Review for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 133: Asia-Pacific 15-Year Perspective for Neuroscience Antibodies and Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers for the Years 2015, 2025 & 2030
- REST OF WORLD
- TABLE 134: Rest of World Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: Rest of World Historic Review for Neuroscience Antibodies and Assays by Technology - Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 136: Rest of World 15-Year Perspective for Neuroscience Antibodies and Assays by Technology - Percentage Breakdown of Value Sales for Immunochemistry / Immunoassays, Molecular Diagnostics, Clinical Chemistry and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 137: Rest of World Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 138: Rest of World Historic Review for Neuroscience Antibodies and Assays by Offering - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 139: Rest of World 15-Year Perspective for Neuroscience Antibodies and Assays by Offering - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
- TABLE 140: Rest of World Recent Past, Current & Future Analysis for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Rest of World Historic Review for Neuroscience Antibodies and Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 142: Rest of World 15-Year Perspective for Neuroscience Antibodies and Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Diagnostic Centers for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates